Clinical Profile and Significance of Delayed Enhanceme

Circulation: Heart Failure

1, 184-191

DOI: 10.1161/circheartfailure.108.768119

Citation Report

#	Article	IF	Citations
2	Implications of Hypertrophic Cardiomyopathy Transmitted by Sperm Donation. JAMA - Journal of the American Medical Association, 2009, 302, 1681.	3.8	43
3	Delayed gadolinium enhancement and elevated plasma brain natriuretic peptide are useful in differentiating hypertrophic cardiomyopathy from athlete's heart. Journal of Cardiology, 2009, 53, 314-315.	0.8	2
4	Shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy. Journal of Magnetic Resonance Imaging, 2009, 30, 967-972.	1.9	29
5	Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Current Heart Failure Reports, 2009, 6, 135-141.	1.3	9
6	The Current and Emerging Role of Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 415-425.	1.1	28
7	The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice. Journal of Cardiovascular Translational Research, 2009, 2, 349-367.	1.1	65
8	Sudden Death in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 368-380.	1.1	32
9	Cardiomyopathies: a revolution in molecular medicine and cardiac imaging. Netherlands Heart Journal, 2009, 17, 456-457.	0.3	8
10	The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2009, 54, 866-875.	1.2	254
11	Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2009, 54, 220-228.	1.2	399
12	Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. British Journal of Sports Medicine, 2009, 43, 649-656.	3.1	117
13	Risk Stratification and Role of Implantable Defibrillators for Prevention of Sudden Death in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2010, 74, 2271-2282.	0.7	65
14	Recent Developments in Outcomes Research in Cardiovascular MRI. Current Cardiovascular Imaging Reports, 2010, 3, 175-186.	0.4	0
15	Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure. Current Cardiology Reports, 2010, 12, 216-222.	1.3	28
16	Management Implications of Massive Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy Significantly Underestimated by Echocardiography but Identified by Cardiovascular Magnetic Resonance. American Journal of Cardiology, 2010, 105, 1842-1843.	0.7	96
17	Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 261-267.	0.7	139
18	Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2010, 3, 51-58.	1.6	364
19	Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Circulation, 2010, 121, 445-456.	1.6	262

#	Article	IF	Citations
20	Myocardial fibrosis assessed by CMR to predict events in HCM. Nature Reviews Cardiology, 2010, 7, 604-606.	6.1	9
21	Risk Stratification in Hypertrophic Cardiomyopathy: Is Two-Dimensional Echocardiographic Strain Ready for Prime Time?. Journal of the American Society of Echocardiography, 2010, 23, 591-594.	1.2	4
22	Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 56, 867-874.	1.2	720
24	Echocardiography in the Era of Multimodality Imaging. Heart Lung and Circulation, 2010, 19, 175-184.	0.2	6
25	Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. European Journal of Radiology, 2010, 74, e149-e153.	1.2	87
26	Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2010, 363, 552-563.	13.9	566
27	Cardiomyopathies: a revolution in molecular medicine and cardiac imaging. Netherlands Heart Journal, 2010, , 1.	0.3	0
28	American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2011, 24, 473-498.	1.2	313
29	Cardiovascular Screening and the Elite Athlete: Advances, Concepts, Controversies, and a View of the Future. Clinics in Sports Medicine, 2011, 30, 503-524.	0.9	7
30	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2011, 58, e212-e260.	1.2	984
31	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2703-2738.	1.2	252
32	Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2011, 4, 1123-1137.	2.3	83
33	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation, 2011, 124, e783-831.	1.6	1,039
34	Late gadolinium enhancement on cardiac magnetic resonance and phenotypic expression in hypertrophic cardiomyopathy. American Heart Journal, 2011, 161, 1073-1077.	1.2	21
35	Imaging of Scar in Patients with Ventricular Arrhythmias of Right Ventricular Origin: Cardiac Magnetic Resonance Versus Electroanatomic Mapping. Journal of Cardiovascular Electrophysiology, 2011, 22, 1359-1366.	0.8	57
36	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1303-1338.	0.4	73
37	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, e153-e203.	0.4	260
38	â€œSpeckledâ€•Ventricular Septum in Hypertrophic Cardiomyopathy Revisited After 30 Years. American Journal of Cardiology, 2011, 107, 1862-1863.	0.7	1

#	Article	IF	Citations
39	The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy. Heart Failure Reviews, 2011, 16, 369-380.	1.7	20
40	Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2011, 13, 67-76.	1.3	7
41	Heart Muscle Diseases. Medical Radiology, 2011, , 275-353.	0.0	0
42	Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2011, 12, 131-139.	0.5	14
43	Coexistence of late gadolinium enhancement due to myocardial infarction and hypertrophic cardiomyopathy. Heart, 2011, 97, 861-862.	1.2	1
44	Hypertrophic Cardiomyopathy: Quantification of Late Gadolinium Enhancement with Contrast-enhanced Cardiovascular MR Imaging. Radiology, 2011, 258, 128-133.	3.6	137
45	2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. Circulation, 2011, 124, 2761-2796.	1.6	725
46	Athlete's Heart and Cardiovascular Care of the Athlete. Circulation, 2011, 123, 2723-2735.	1.6	226
47	Hypertrophic Cardiomyopathy Mimicking Acute Anterior Myocardial Infarction Associated with Sudden Cardiac Death. Case Reports in Medicine, 2012, 2012, 1-4.	0.3	3
49	Patterns of Disease Progression in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2012, 5, 535-546.	1.6	258
50	Systolic Myocardial Mechanics in Patients with Andersonâ€“Fabry Disease with and without Left Ventricular Hypertrophy and in Comparison to Nonobstructive Hypertrophic Cardiomyopathy. Echocardiography, 2012, 29, 810-817.	0.3	39
51	A Primer on Arrhythmias in Patients with Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2012, 14, 552-562.	1.3	13
52	Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2012, 13, 617-623.	0.5	153
53	Predicting the Future in Hypertrophic Cardiomyopathy: From Histopathology To Flow To Function. Journal of the American Society of Echocardiography, 2012, 25, 190-193.	1.2	1
54	The coronary circulation and blood flow in left ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2012, 52, 857-864.	0.9	144
55	Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart, 2012, 98, 438-442.	1.2	61
56	Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 7.	1.6	244
57	The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 12.	1.6	141

#	Article	IF	Citations
58	Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 33.	1.6	99
59	Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 70.	1.6	120
60	Progression of Myocardial Fibrosis Assessed With Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2012, 60, 922-929.	1.2	123
61	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2012, 60, 930-931.	1.2	4
62	Prognostic Value of Late Gadolinium Enhancement in Clinical Outcomes for Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2012, 5, 370-377.	2.3	369
63	LGE and the Risk of Sudden Death in HCM. JACC: Cardiovascular Imaging, 2012, 5, 761-762.	2.3	6
65	Incremental Value of Late Gadolinium Enhancement for Management of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 1207-1212.	0.7	20
66	In patients with hypertrophic cardiomyopathy myocardial fi brosis is associated with both left ventricular and left atrial dysfunction. Acta Cardiologica, 2012, 67, 187-193.	0.3	21
67	Hypertrophic Cardiomyopathy in Infants and Children. , 0, , .		0
68	Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2012, 5, 78-85.	1.3	59
69	Hypertrophic Cardiomyopathy in 2012. Circulation, 2012, 125, 1432-1438.	1.6	69
72	Role of Multimodality Imaging in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Seminars in Roentgenology, 2012, 47, 253-261.	0.2	2
73	Myocardial Fibrosis Is Associated with Biventricular Dysfunction in Patients with Hypertrophic Cardiomyopathy. Echocardiography, 2012, 29, 438-444.	0.3	19
74	Evolving diagnostic and prognostic imaging of the various cardiomyopathies. Annals of the New York Academy of Sciences, 2012, 1254, 123-130.	1.8	5
75	Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR. Nuclear Medicine and Molecular Imaging, 2013, 47, 196-200.	0.6	20
76	Myocardial Fibrosis in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2013, 6, 587-596.	2.3	175
77	Genetic Etiology and Evaluation of Sudden Cardiac Death. Current Cardiology Reports, 2013, 15, 389.	1.3	6
78	The Prognostic Value of Late Gadolinium Enhancement CMR in Nonischemic Cardiomyopathies. Current Cardiology Reports, 2013, 15, 326.	1.3	14

#	Article	IF	Citations
79	MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease. Japanese Journal of Radiology, 2013, 31, 693-700.	1.0	20
80	Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy. Canadian Journal of Cardiology, 2013, 29, 358-363.	0.8	57
81	T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. Circulation: Cardiovascular Imaging, 2013, 6, 415-422.	1.3	195
82	Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. International Journal of Cardiovascular Imaging, 2013, 29, 191-197.	0.7	27
83	Cardiac Magnetic Resonance Imaging: Recent Advances and New Insights in Cardiovascular Disease. Current Cardiovascular Imaging Reports, 2013, 6, 34-44.	0.4	1
84	Significance of High-Sensitivity Cardiac Troponin T in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 1252-1259.	1.2	110
85	Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers Without Left Ventricular Hypertrophy. Circulation: Cardiovascular Genetics, 2013, 6, 230-237.	5.1	58
86	Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy â‰¥60 Years of Age. Circulation, 2013, 127, 585-593.	1.6	200
87	Determining the role of fibrosis in hypertrophic cardiomyopathy. Expert Review of Cardiovascular Therapy, 2013, 11, 495-504.	0.6	10
88	Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2013, 6, 210-217.	1.3	54
89	Advances of cardiovascular MRI in hypertrophic cardiomyopathy. Future Cardiology, 2013, 9, 697-709.	0.5	1
90	Extent of Late Gadolinium Enhancement on Cardiovascular Magnetic Resonance Imaging and Its Relation to Left Ventricular Longitudinal Functional Reserve During Exercise in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2013, 77, 1742-1749.	0.7	19
91	2014 Korean Guidelines for Appropriate Utilization of Cardiovascular Magnetic Resonance Imaging: A Joint Report of the Korean Society of Cardiology and the Korean Society of Radiology. Korean Journal of Radiology, 2014, 15, 659.	1.5	26
92	2014 Korean Guidelines for Appropriate Utilization of Cardiovascular Magnetic Resonance Imaging: A Joint Report of the Korean Society of Cardiology and the Korean Society of Radiology. Korean Circulation Journal, 2014, 44, 359.	0.7	12
93	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 2014, 100, 1851-1858.	1.2	144
94	ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathy. Open Heart, 2014, 1, e000101.	0.9	9
95	Established and emerging cardiovascular magnetic resonance techniques for prognostication and guiding therapy in heart failure. Expert Review of Cardiovascular Therapy, 2014, 12, 45-55.	0.6	4
96	Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 85.	1.6	76

#	Article	IF	Citations
97	Magnetic Resonance Imaging for Hypertrophic Cardiomyopathy Update. Topics in Magnetic Resonance Imaging, 2014, 23, 33-41.	0.7	2
98	Perspectives on Sudden Death Prevention in Hypertrophic Cardiomyopathy. Cardiology in Review, 2014, 22, 210-216.	0.6	10
99	The Prognostic Impact of Myocardial Late Gadolinium Enhancement. Cardiology in Review, 2014, 22, 128-139.	0.6	6
100	Myocardial Tissue Characterization With Magnetic Resonance Imaging. Journal of Thoracic Imaging, 2014, 29, 318-330.	0.8	12
102	A Rare Case of Hypertrophic Cardiomyopathy with Subendocardial Late Gadolinium Enhancement in an Apical Aneurysm with Thrombus. Case Reports in Radiology, 2014, 2014, 1-5.	0.5	3
103	Cardiac Magnetic Resonance Imaging Findings Predict Major Adverse Events in Apical Hypertrophic Cardiomyopathy. Journal of Thoracic Imaging, 2014, 29, 331-339.	0.8	33
104	Reply. Journal of the American College of Cardiology, 2014, 63, 2055.	1.2	0
105	Reply. Journal of the American College of Cardiology, 2014, 63, 2054-2055.	1.2	0
106	The emerging role of cardiovascular MRI for risk stratification in hypertrophic cardiomyopathy. Clinical Radiology, 2014, 69, 221-230.	0.5	15
107	MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology, 2014, 273, 329-348.	3.6	60
108	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783
109	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
110	Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 261-267.	0.2	3
112	Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 49.	1.6	73
113	Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors. American Journal of Cardiology, 2014, 113, 1550-1555.	0.7	107
114	Prevalence and determinants of elevated high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. Journal of Cardiology, 2014, 63, 140-144.	0.8	25
115	Prognostic Value of Myocardial Scar in Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 2055.	1.2	0
116	Left Atrial Remodeling in Hypertrophic Cardiomyopathy and Susceptibility Markers for Atrial Fibrillation Identified by Cardiovascular Magnetic Resonance. American Journal of Cardiology, 2014, 113, 1394-1400.	0.7	95

#	Article	IF	Citations
117	ExpressÃ£o fenotÃpica da miocardiopatia hipertrÃ³fica e realce tardio na ressonÃ¢ncia magnÃ©tica cardÃaca. Revista Portuguesa De Cardiologia, 2014, 33, 261-267.	0.2	5
118	Prognostic Value of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in Japanese Hypertrophic Cardiomyopathy Patients. Circulation Journal, 2014, 78, 929-937.	0.7	35
119	Myocardial Repolarization Dispersion and Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2014, 78, 1216-1223.	0.7	11
120	Late Gadolinium Enhancement and Prognosis of Hypertrophic Cardiomyopathy. Circulation Journal, 2014, 78, 832-834.	0.7	8
121	Delayed Enhancement Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy With Basal Septal Hypertrophy and Preserved Ejection Fraction. Journal of Computer Assisted Tomography, 2014, 38, 67-71.	0.5	14
122	The Implications and Assessment of Myocardial Fibrosis in Older Cardiovascular Patients. Current Geriatrics Reports, 2015, 4, 362-367.	1.1	0
123	Cardiac Magnetic Resonance Imaging in Ventricular Remodelling. Current Cardiovascular Imaging Reports, 2015, 8, 1.	0.4	0
124	Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy. Congenital Heart Disease, 2015, 10, E258-E267.	0.0	27
125	The Role of Cardiovascular Magnetic Resonance in Sudden Death Risk Stratification in Hypertrophic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 187-193.	0.7	13
126	Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy â€" comparison with late enhancement quantification. Magnetic Resonance Imaging, 2015, 33, 718-724.	1.0	32
127	Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy. Heart, 2015, 101, 870-876.	1.2	32
128	Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart, 2015, 101, 1406-1411.	1.2	123
129	Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance. European Heart Journal Cardiovascular Imaging, 2015, 16, 29-36.	0.5	22
130	Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients. Journal of Cardiology, 2015, 66, 520-526.	0.8	34
132	The Role of Echocardiography in Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2015, 17, 6.	1.3	4
133	Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction. European Radiology, 2015, 25, 1190-1200.	2.3	13
134	Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. European Heart Journal Cardiovascular Imaging, 2015, 16, 280-280.	0.5	214
135	Role of Imaging in the Evaluation of Patients at Risk for Sudden Cardiac Death. JACC: Cardiovascular Imaging, 2015, 8, 828-845.	2.3	11

#	Article	IF	Citations
136	Overview of Myocardial T1 Mapping Applications. Current Radiology Reports, 2015, 3, 1.	0.4	0
137	Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy. Current Cardiovascular Imaging Reports, 2015, 8, 1.	0.4	0
138	Unravelling the grey zone: cardiac MRI volume to wall mass ratio to differentiate hypertrophic cardiomyopathy and the athlete's heart. British Journal of Sports Medicine, 2015, 49, 1404-1409.	3.1	15
141	Cardiac Imaging in Hypertrophic Cardiomyopathy. , 0, , .		0
142	Cardiovascular magnetic resonance in hypertrophic cardiomyopathy and infiltrative cardiomyopathy. South African Journal of Radiology, 2016, 20, .	0.1	0
143	Left Atrial Mechanical Function and Global Strain in Hypertrophic Cardiomyopathy. PLoS ONE, 2016, 11, e0157433.	1.1	21
144	Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2016, 27, 571-580.	0.8	56
145	Late Gadolinium Enhancement in Patients with Nonischemic Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 731-747.	0.5	16
146	Quantitative comparison of 2D and 3D late gadolinium enhancement MR imaging in patients with Fabry disease and hypertrophic cardiomyopathy. International Journal of Cardiology, 2016, 217, 167-173.	0.8	10
147	Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. Journal of the American Society of Echocardiography, 2016, 29, 622-639.	1.2	50
148	Imaging for assessment of sudden death risk: current role and future prospects. Europace, 2016, 18, 1491-1500.	0.7	7
149	Diagnostic and prognostic roles of echocardiography and cardiac magnetic resonance. Journal of Nuclear Cardiology, 2016, 23, 1399-1410.	1.4	7
150	Extent of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in Japanese Hypertrophic Cardiomyopathy Patients. Circulation Journal, 2016, 80, 950-957.	0.7	11
151	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	1.6	103
152	Prognostic Value of LGE-CMR in HCM. JACC: Cardiovascular Imaging, 2016, 9, 1392-1402.	2.3	319
153	Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis. International Journal of Cardiovascular Imaging, 2016, 32, 613-620.	0.7	6
154	Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?. European Heart Journal Cardiovascular Imaging, 2016, 17, 293-300.	0.5	16
155	Unexpectedly low left ventricular voltage on ECG in hypertrophic cardiomyopathy. Heart, 2016, 102, 292-297.	1.2	3

#	Article	IF	Citations
156	Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2016, 17, 613-621.	0.5	184
158	The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Journal of Cardiology, 2016, 68, 49-56.	0.8	42
159	Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart and Vessels, 2016, 31, 758-770.	0.5	16
160	Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. Heart and Vessels, 2017, 32, 166-174.	0.5	17
161	Delayed Myocardial Enhancement in Pediatric Hypertrophic Cardiomyopathy: Correlation with LV Function, Echocardiography, and Demographic Parameters. Pediatric Cardiology, 2017, 38, 1024-1031.	0.6	8
162	Cardiac Applications of PET-MR. Current Cardiology Reports, 2017, 19, 42.	1.3	9
163	A Good Heart Is Hard to Find. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	0
164	CMR in Phenotyping the Arrhythmic Substrate. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.4	0
165	Mechanical dispersion and global longitudinal strain by speckle tracking echocardiography: Predictors of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy. Echocardiography, 2017, 34, 835-842.	0.3	32
166	Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. European Radiology, 2017, 27, 5136-5145.	2.3	53
167	Clinical recommendations of cardiac magnetic resonance, Part II. Journal of Cardiovascular Medicine, 2017, 18, 209-222.	0.6	22
168	<scp>ESC</scp> suddenâ€death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrastâ€enhanced <scp>CMR</scp> in intermediateâ€risk patients. Clinical Cardiology, 2017, 40, 853-860.	0.7	11
169	Structural and Functional Correlates of Myocardial T1 Mapping in 321 Patients With Hypertrophic Cardiomyopathy. Journal of Computer Assisted Tomography, 2017, 41, 653-660.	0.5	6
170	Fabry Disease in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
171	Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity. Current Cardiology Reports, 2017, 19, 65.	1.3	10
172	Integrated Imaging in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 328-339.	0.7	13
173	Comparison of echocardiography with tissue Doppler imaging and magnetic resonance imaging with delayed enhancement in the assessment of children with hypertrophic cardiomyopathy. Archives of Medical Science, 2017, 2, 328-336.	0.4	14
174	Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2018, 7, .	1.6	47

#	Article	IF	Citations
175	Clinical applications of multiparametric CMR in left ventricular hypertrophy. International Journal of Cardiovascular Imaging, 2018, 34, 577-585.	0.7	13
176	Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 782-792.	1.6	72
177	European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athleteâ€™s heart. European Heart Journal, 2018, 39, 1949-1969.	1.0	224
178	Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance. International Journal of Cardiovascular Imaging, 2018, 34, 121-129.	0.7	21
179	The Prognostic Implications of Two-Dimensional Speckle Tracking Echocardiography in Hypertrophic Cardiomyopathy. Cardiology in Review, 2018, 26, 130-136.	0.6	17
180	Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy. Heart and Vessels, 2018, 33, 513-520.	0.5	8
181	Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 122-126.	0.8	43
182	Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2018, 2018, 22.	0.3	18
183	PrediccÃ³n del riesgo de muerte sÃºbita cardiaca: elÂpapel deÂlaÂresonancia magnÃ©tica cardiaca. Revista Espanola De Cardiologia, 2018, 71, 961-970.	0.6	10
184	OBSOLETE: Managing Cardiovascular Disease in Sport and Athletes. , 2018, , .		0
185	Sudden Cardiac Death Risk Prediction: The Role of Cardiac Magnetic Resonance Imaging. Revista Espanola De Cardiologia (English Ed), 2018, 71, 961-970.	0.4	11
187	Managing Cardiovascular Disease in Sport and Athletes. , 2018, , 302-315.		0
188	LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results. European Radiology, 2018, 28, 4615-4624.	2.3	56
189	Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Archives of Cardiovascular Diseases, 2018, 111, 591-600.	0.7	11
190	Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?. Journal of Nuclear Cardiology, 2019, 26, 1125-1134.	1.4	11
191	Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?. Journal of Nuclear Cardiology, 2019, 26, 1135-1137.	1.4	2
192	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. American Journal of Cardiology, 2019, 124, 1286-1292.	0.7	38
193	The Role of Contrast-Enhanced Cardiac Magnetic Resonance in the Assessment of Patients with Malignant Ventricular Arrhythmias. Magnetic Resonance Imaging Clinics of North America, 2019, 27, 475-490.	0.6	0

#	Article	IF	Citations
194	Assessment of Cardiomyopathies and Cardiac Transplantation. Contemporary Cardiology, 2019, , 249-272.	0.0	0
195	The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tpâ€e interval, 5â€year sudden cardiac death risk score in hypertrophic cardiomyopathy patients. Annals of Noninvasive Electrocardiology, 2019, 24, e12672.	0.5	5
196	Differences in the extent of fibrosis in obstructive and nonobstructive hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2019, 20, 389-396.	0.6	3
197	Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). European Heart Journal, 2019, 40, 19-33.	1.0	288
198	Sudden Cardiac Death Risk Assessment. , 2019, , 145-155.		0
199	Epicardial and Microvascular Ischemia: Implications, Diagnosis, and Management. , 2019, , 263-273.		0
200	Approach to theÂInitial and Follow-Up Visits. , 2019, , 389-406.		0
201	Longitudinal Case-Based Presentations in HCM. , 2019, , 429-468.		0
202	Cardiac Magnetic Resonance for Diagnosis and Risk Stratification. Cardiology Clinics, 2019, 37, 27-33.	0.9	12
204	Risk stratification in hypertrophic cardiomyopathy. Herz, 2020, 45, 50-64.	0.4	7
205	Left Ventricular Hypertrophy: Evaluation With Cardiac MRI. Current Problems in Diagnostic Radiology, 2020, 49, 460-475.	0.6	16
206	Elevation of highâ€sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy. ESC Heart Failure, 2020, 7, 3593-3600.	1.4	14
207	Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis. Progress in Cardiovascular Diseases, 2021, 66, 10-16.	1.6	14
208	Late gadolinium enhancement location assessed by magnetic resonance and arrhythmogenic risk in hypertrophic cardiomyopathy. Revista Portuguesa De Cardiologia, 2020, 39, 615-621.	0.2	4
209	MRI Characteristics, Prevalence, and Outcomes of Hypertrophic Cardiomyopathy with Restrictive Phenotype. Radiology: Cardiothoracic Imaging, 2020, 2, e190158.	0.9	6
210	Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle. Heart Failure Reviews, 2022, 27, 49-69.	1.7	10
211	Late Gadolinium Enhancementâ€“Dispersion Mapping. Circulation: Cardiovascular Imaging, 2020, 13, e010489.	1.3	17
212	The Role of MRI in Prognostic Stratification of Cardiomyopathies. Current Cardiology Reports, 2020, 22, 61.	1.3	5

#	Article	IF	Citations
213	Cardiac Magnetic Resonance Imaging Features in Hypertrophic Cardiomyopathy Diagnosed at <21 Years of Age. American Journal of Cardiology, 2020, 125, 1249-1255.	0.7	8
214	Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study. Canadian Journal of Physiology and Pharmacology, 2020, 98, 459-465.	0.7	3
215	Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging. Heart Failure Reviews, 2021, 26, 1023-1036.	1.7	17
216	Coronary microvascular dysfunction in hypertrophic cardiomyopathy: Pathophysiology, assessment, and clinical impact. Microcirculation, 2021, 28, e12656.	1.0	20
217	Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 947-958.	2.3	41
218	Segmental longitudinal strain as the most accurate predictor of the patchy pattern late gadolinium enhancement in hypertrophic cardiomyopathy. Journal of Cardiology, 2021, 77, 475-481.	0.8	8
219	Hypertrophic Cardiomyopathy in Pregnancy. Cardiology Clinics, 2021, 39, 143-150.	0.9	7
220	Improvement of late gadolinium enhancement image quality using a deep learningâ€“based reconstruction algorithm and its influence on myocardial scar quantification. European Radiology, 2021, 31, 3846-3855.	2.3	31
221	When to Use Cardiovascular Magnetic Resonance in Patients with Heart Failure. Heart Failure Clinics, 2021, 17, 1-8.	1.0	2
222	Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheterization and Cardiovascular Interventions, 2021, 98, 393-400.	0.7	6
223	Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007022.	1.6	58
224	A simple algorithm for a clinical step-by-step approach in the management of hypertrophic cardiomyopathy. Future Cardiology, 2021, 17, 1395-1405.	0.5	0
225	Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy. , 0, , .		0
226	Patterns of Left Ventricular Hypertrophy and Late Gadolinium Enhancement on Cardiac MRI in Patients with Hypertrophic Cardiomyopathy and their Prognostic Significance â€“ An Experience from a South Asian Country. Journal of Clinical Imaging Science, 2021, 11, 14.	0.4	5
227	Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 647857.	1.1	11
228	JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. Circulation Journal, 2021, 85, 1590-1689.	0.7	45
230	Ventricular diastolic dimension over maximal myocardial thickness is robust landmark of systolic impairment in patients with hypertrophic cardiomyopathy. Medical Science Monitor, 2018, 24, 1880-1886.	0.5	2
231	Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype. Diagnostics, 2020, 10, 770.	1.3	19

#	Article	IF	Citations
232	The role of magnetic resonance imaging in hypertrophic cardiomyopathy. Quantitative Imaging in Medicine and Surgery, 2014, 4, 397-406.	1.1	22
234	The usefulness of cardiovascular magnetic resonance imaging in children with myocardial diseases. Kardiologia Polska, 2015, 73, 419-428.	0.3	5
235	The Arrhythmic Phenotype in Cardiomyopathy. Heart Failure Clinics, 2021, 18, 101-113.	1.0	0
236	Ventricular arrhythmias and sudden death in hypertrophic cardiomyopathy. Cor Et Vasa, 2010, 52, 441-446.	0.1	1
237	Spatio-temporal Registration of 2D US and 3D MR Images for the Characterization of Hypertrophic Cardiomyopathy. Lecture Notes in Computer Science, 2013, , 292-299.	1.0	2
238	Other Imaging Techniques in Hypertrophic Cardiomyopathy. , 2014, , 117-129.		0
239	Approach to the Initial and Follow-Up Visits. , 2015, , 255-268.		0
240	Natural History of Untreated Hypertrophic Cardiomyopathy. , 2015, , 9-22.		0
241	Longitudinal Case Based Presentations in HCM. , 2015, , 287-321.		0
242	Sudden Cardiac Death Risk Assessment. , 2015, , 123-131.		0
244	2014 Korean Guidelines for Appropriate Utilization of Cardiovascular Magnetic Resonance Imaging: A Joint Report of the Korean Society of Cardiology and the Korean Society of Radiology. Journal of the Korean Society of Radiology, 2015, 72, 217.	0.1	0
245	Reproducibility of Gadolinium Enhancement Patterns and Wall Thickness in Hypertrophic Cardiomyopathy. Arquivos Brasileiros De Cardiologia, 2016, 107, 48-54.	0.3	1
246	The Effect of Diazepam on the Function of Hypertrophied Ratsâ€™ Hearts in Ischemia-Reperfusion Conditions. International Cardiovascular Research Journal, 2016, 10, 89-94.	0.2	2
247	The Potential of Late Gadolinium Enhancement to Serve as a Predictor of Ventricular Arrhythmias in Hypertrophic Cardio-myopathy Patients. Open Hypertension Journal, 2016, 8, 1-11.	0.8	0
248	Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications. International Cardiovascular Forum Journal, 0, 8, .	1.1	0
249	Cardiac MRI Assessment of Myocardial Damages Associated with Hypertrophic Cardiomyopathy. Journal of the Nihon University Medical Association, 2017, 76, 100-103.	0.0	0
250	A Systematic review for sudden cardiac death in hypertrophic cardiomyopathy patients with Myocardial Fibrosis: A CMR LGE Study. Journal of Cardiology and Cardiovascular Medicine, 2019, 4, 187-191.	0.1	0
251	Late gadolinium enhancement location assessed by magnetic resonance and arrhythmogenic risk in hypertrophic cardiomyopathy. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 615-621.	0.2	1

#	Article	IF	Citations
252	The Relationship between Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis and Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. Journal of Personalized Medicine, 2022, 12, 294.	1.1	1
253	Associations between perfusion defects, tissue changes and myocardial deformation in hypertrophic cardiomyopathy, uncovered by a cardiac magnetic resonance segmental analysis. Revista Portuguesa De Cardiologia, 2022, 41, 559-568.	0.2	5
254	Role of cardiac magnetic resonance imaging in predicting atrial fibrillation in patients with hypertrophic cardiomyopathy. Cukurova Medical Journal, 2022, 47, 811-819.	0.1	0
256	Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging. Biology of Sex Differences, 2022, 13, .	1.8	4
257	Index of microcirculatory resistance in the assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Revista Portuguesa De Cardiologia, 2022, 41, 761-767.	0.2	2
258	Preoperative myocardial fibrosis is associated with worse survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: A delayed enhanced cardiac magnetic resonance study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
259	å¿ƒè‡“MRIã§æ¯”è¼ƒçš„çŸæœŸé–“ã§ã®å¿ƒç‹éšœå®³ã®é€²å±•ã‚’æŽã‚‰ã‹ã«ã—ãŸã‚ï¼Œæ¿ƒåŽšã—ãŸå®¶æ—æ´ã‚’æœ‰ã™ã‚‹å§åž‹å¿...		
260	Multimodality Imaging in Sarcomeric Hypertrophic Cardiomyopathy: Get It Rightâ€¦on Time. Life, 2023, 13, 171.	1.1	2
261	Microvascular Dysfunction Is Associated With Impaired Myocardial Work in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Multimodality Study. Journal of the American Heart Association, 2023, 12, .	1.6	4